Patent Evaluation: Sulphonic Acid Stilbenes as Antiviral Agents: Current Opinion on Therapeutic Patents: Vol 2, No 11

Views

CrossRef citations to date

Altmetric

Summary

Novelty: Novel sulphonic acid stilbenes are claimed to be useful for the treatment of HIV, HSV and CMV infections.

Biology: In vitro antiviral activity was assessed against HIV-1 infected human T-cell line JM. 4,4-Di-isothiocyanatodihydrostilbene-2,2-disulphonic acid (DIDS) was the most active compound, giving 93.6% control at 50μM; this was determined by following the dose-dependent inhibition of p24 viral core antigen.

Chemistry: The preparation of the novel compounds is described briefly. Three compounds are specifically claimed, including DIDS.

Structure:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Patent Evaluation: Sulphonic Acid Stilbenes as Antiviral Agents

Information for

Open access

Opportunities

Help and information

Patent Evaluation: Sulphonic Acid Stilbenes as Antiviral Agents

Summary

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature